Neuro-signaling research
Semax
Lyophilized neuro-signaling research peptide
Semax is an ACTH-fragment research peptide discussed in neurotrophic, stress-response, and central nervous system literature.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
研究背景
Semax 研究プロファイル
Semax is a synthetic peptide derived from the ACTH(4-7) fragment and extended with a Pro-Gly-Pro sequence. Research explores neurotrophic signaling, BDNF-related markers, stress responses, gene expression, neurotransmission, and experimental models of neural injury or cognitive performance. It is distinct from Selank, a tuftsin analog studied more often in stress and neuroimmune contexts, and from DSIP, which is associated with sleep-adjacent literature. Semax is best selected when the project specifically requires an ACTH-fragment neuro-signaling reference. Much of the literature is preclinical or regional, and variations in study quality and experimental design should be considered when interpreting results.
想定される機序
An ACTH(4-7)-derived peptide extended with Pro-Gly-Pro. No single receptor mechanism is established; proposed pathways include changes in BDNF and NGF expression, melanocortin-related signaling, monoamine systems, inflammatory pathways, and transcription after neural stress.
研究で報告された作用
- Cell and animal studies report altered BDNF-related expression, neuroprotection, inflammatory markers, and outcomes in ischemia or neural-injury models.
- Behavioral studies in animals report changes in learning, attention, stress response, and locomotor endpoints.
- Human evidence is limited, regionally concentrated, and not sufficient to establish broad cognitive or neuroprotective effects.
一般的な研究エンドポイント
BDNF and NGF expression, monoamines, inflammatory cytokines, infarct or injury measures, neuronal survival, learning and memory tasks, stress behavior, EEG, and pharmacokinetics.
エビデンスと限界
The literature is primarily preclinical with limited regional clinical work. Mechanism, reproducibility, and generalizable human effects remain uncertain.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
